Does the media favor IONS or ALNY?

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 7 mentions for Ionis Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.61 beat Ionis Pharmaceuticals' score of 1.08 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor BIIB or IONS?

In the previous week, Biogen had 4 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 11 mentions for Biogen and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Biogen's score of 0.49 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ionis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IONS or UTHR?

In the previous week, United Therapeutics had 15 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 22 mentions for United Therapeutics and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat United Therapeutics' score of 0.74 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IONS or INCY?

In the previous week, Incyte had 4 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 11 mentions for Incyte and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Incyte's score of 0.21 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer NBIX or IONS?

In the previous week, Neurocrine Biosciences had 6 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 13 mentions for Neurocrine Biosciences and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Neurocrine Biosciences' score of 0.58 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ionis Pharmaceuticals (IONS) Competitors

$76.50 -0.83 (-1.07%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$78.58 +2.08 (+2.72%)

As of 05/29/2026 07:15 PM Eastern

Compare

IONS vs. ALNY, BIIB, UTHR, INCY, and NBIX

Should you buy Ionis Pharmaceuticals stock or one of its competitors? MarketBeat compares Ionis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ionis Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Alnylam Pharmaceuticals has a net margin of 11.72% compared to Ionis Pharmaceuticals' net margin of -30.91%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

Ionis Pharmaceuticals presently has a consensus price target of $100.90, indicating a potential upside of 31.90%. Alnylam Pharmaceuticals has a consensus price target of $463.13, indicating a potential upside of 53.37%. Given Alnylam Pharmaceuticals' higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.90
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 2.6% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$1.06B	11.95	-$381.39M	-$2.07	N/A
Alnylam Pharmaceuticals	$3.71B	10.86	$313.75M	$3.66	82.51

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 7 mentions for Ionis Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.61 beat Ionis Pharmaceuticals' score of 1.08 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ionis Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Ionis Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Biogen has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.93	$1.29B	$9.32	21.03
Ionis Pharmaceuticals	$1.06B	11.95	-$381.39M	-$2.07	N/A

Biogen has a net margin of 13.81% compared to Ionis Pharmaceuticals' net margin of -30.91%. Biogen's return on equity of 12.83% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%

Biogen presently has a consensus target price of $215.81, indicating a potential upside of 10.11%. Ionis Pharmaceuticals has a consensus target price of $100.90, indicating a potential upside of 31.90%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.90

87.9% of Biogen shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 2.6% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biogen had 4 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 11 mentions for Biogen and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Biogen's score of 0.49 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ionis Pharmaceuticals beats Biogen on 9 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to United Therapeutics?

Ionis Pharmaceuticals (NASDAQ:IONS) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$1.06B	11.95	-$381.39M	-$2.07	N/A
United Therapeutics	$3.18B	7.43	$1.33B	$27.09	20.55

United Therapeutics has a net margin of 40.62% compared to Ionis Pharmaceuticals' net margin of -30.91%. United Therapeutics' return on equity of 19.24% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%
United Therapeutics	40.62%	19.24%	17.25%

Ionis Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Ionis Pharmaceuticals currently has a consensus price target of $100.90, suggesting a potential upside of 31.90%. United Therapeutics has a consensus price target of $619.42, suggesting a potential upside of 11.24%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.90
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 2.6% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, United Therapeutics had 15 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 22 mentions for United Therapeutics and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat United Therapeutics' score of 0.74 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

United Therapeutics beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Incyte?

Ionis Pharmaceuticals (NASDAQ:IONS) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 2.6% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Incyte has a net margin of 26.71% compared to Ionis Pharmaceuticals' net margin of -30.91%. Incyte's return on equity of 26.66% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%
Incyte	26.71%	26.66%	19.77%

Incyte has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$1.06B	11.95	-$381.39M	-$2.07	N/A
Incyte	$5.14B	3.76	$1.29B	$7.08	13.66

In the previous week, Incyte had 4 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 11 mentions for Incyte and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Incyte's score of 0.21 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ionis Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Ionis Pharmaceuticals currently has a consensus price target of $100.90, suggesting a potential upside of 31.90%. Incyte has a consensus price target of $104.00, suggesting a potential upside of 7.50%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.90
Incyte	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Summary

Incyte beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Neurocrine Biosciences had 6 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 13 mentions for Neurocrine Biosciences and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Neurocrine Biosciences' score of 0.58 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$3.10B	5.13	$478.60M	$6.49	24.39
Ionis Pharmaceuticals	$1.06B	11.95	-$381.39M	-$2.07	N/A

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 2.6% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Neurocrine Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Neurocrine Biosciences presently has a consensus price target of $186.05, suggesting a potential upside of 17.53%. Ionis Pharmaceuticals has a consensus price target of $100.90, suggesting a potential upside of 31.90%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.83
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.90

Neurocrine Biosciences has a net margin of 21.55% compared to Ionis Pharmaceuticals' net margin of -30.91%. Neurocrine Biosciences' return on equity of 19.79% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%

Summary

Neurocrine Biosciences beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Ionis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IONS vs. The Competition

Export

Metric	Ionis Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.64B	$3.03B	$5.82B	$12.56B
Dividend Yield	N/A	1.97%	2.69%	5.31%
P/E Ratio	-36.96	18.29	21.63	26.27
Price / Sales	11.95	817.51	626.55	142.41
Price / Cash	N/A	56.70	43.22	56.84
Price / Book	25.76	6.31	10.55	7.30
Net Income	-$381.39M	$75.84M	$3.56B	$337.27M
7 Day Performance	1.24%	2.83%	2.85%	3.58%
1 Month Performance	2.33%	0.15%	4.59%	5.71%
1 Year Performance	127.41%	32.89%	37.62%	39.70%

Ionis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IONS Ionis Pharmaceuticals	3.2806 of 5 stars	$76.50 -1.1%	$100.90 +31.9%	+127.4%	$12.64B	$1.06B	N/A	1,402	Positive News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.4352 of 5 stars	$297.45 flat	$463.13 +55.7%	-0.9%	$39.71B	$3.71B	81.27	2,770	Positive News
BIIB Biogen	3.3044 of 5 stars	$193.76 flat	$215.62 +11.3%	+49.5%	$28.61B	$9.89B	20.79	7,500	Analyst Forecast
UTHR United Therapeutics	4.1762 of 5 stars	$568.43 flat	$619.42 +9.0%	+76.0%	$24.13B	$3.18B	20.98	1,400	Trending News Insider Trade
INCY Incyte	4.2944 of 5 stars	$97.16 flat	$104.00 +7.0%	+48.3%	$19.41B	$5.14B	13.72	2,844

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IONS) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Ionis Pharmaceuticals compare to Biogen?

Summary

How does Ionis Pharmaceuticals compare to United Therapeutics?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Summary

How does Ionis Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Is IONS or ALNY more profitable?

Do analysts prefer IONS or ALNY?

Do insiders & institutionals believe in IONS or ALNY?

Which has stronger earnings & valuation, IONS or ALNY?

Does the media favor IONS or ALNY?

Which has more volatility & risk, IONS or ALNY?

Summary

How does Ionis Pharmaceuticals compare to Biogen?

Which has more volatility and risk, BIIB or IONS?

Which has preferable earnings & valuation, BIIB or IONS?

Is BIIB or IONS more profitable?

Do analysts prefer BIIB or IONS?

Do insiders and institutionals believe in BIIB or IONS?

Does the media favor BIIB or IONS?

Summary

How does Ionis Pharmaceuticals compare to United Therapeutics?

Which has stronger earnings and valuation, IONS or UTHR?

Is IONS or UTHR more profitable?

Which has more volatility and risk, IONS or UTHR?

Do analysts rate IONS or UTHR?

Do insiders & institutionals hold more shares of IONS or UTHR?

Does the media prefer IONS or UTHR?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Do institutionals & insiders hold more shares of IONS or INCY?

Is IONS or INCY more profitable?

Which has higher earnings & valuation, IONS or INCY?

Does the media favor IONS or INCY?

Which has more risk and volatility, IONS or INCY?

Do analysts recommend IONS or INCY?

Summary

How does Ionis Pharmaceuticals compare to Neurocrine Biosciences?

Does the media prefer NBIX or IONS?

Which has higher earnings and valuation, NBIX or IONS?

Do institutionals & insiders hold more shares of NBIX or IONS?

Which has more volatility & risk, NBIX or IONS?

Do analysts recommend NBIX or IONS?

Is NBIX or IONS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools